Despite Challenges, Strategic Repurchases and Solar Project Advancements Highlight Strong Quarter
Teva stock surged to a five-year high Wednesday after the drugmaker kept its full-year guidance despite missing first-quarter profit views.
Strong Start to 2024 with Significant Revenue Growth and Strategic Financial Management